SNCA and posterior cortical atrophy: For translational research, Jafari et al. [34] reviewed the latest findings in the field of immune checkpoints for PCa application, such as CTLA-4, PD-1, PD-L1, B7-H3, etc., and potential biomarkers correlated with immune infiltrates in tumor microenvironment are also identified for providing candidate PCa therapeutic targets [35].